Discount Agreement for Budesonide (Kinpeygo and interchangeable medicines)

Discount Agreement for Clonazepam (Active Ingredient)

DAK-Gesundheit is entering into non-exclusive discount agreements for the active ingredient Clonazepam. The goal is to provide access to all interested pharmaceutical companies until new agreements take effect.

DAK-Gesundheit

Discount Agreement for Nifedipine (ATC C08CA05)

DAK-Gesundheit is entering into non-exclusive discount agreements for Nifedipine, facilitating access for all interested pharmaceutical companies. This agreement runs from 01.08.2026 to 31.07.2028 with a renewal option.

DAK-Gesundheit

Discount Agreement for Granisetron (ILO) by DAK-Gesundheit

Enter into a non-exclusive discount agreement for Granisetron (ILO) with DAK-Gesundheit. Valid from August 1, 2026, to July 31, 2028, with a one-year extension option.

DAK-Gesundheit

Discount Agreement for Palonosetron (WKA) with DAK-Gesundheit

Enter into a non-exclusive discount agreement for Palonosetron (WKA) with DAK-Gesundheit. The contract runs from 08/01/2026 to 07/31/2028 with a renewal option.

DAK-Gesundheit